CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −12,500 | 7,500 | ||
| 2025-11-04 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −6,250 | 18,750 | ||
| 2025-11-03 | Heerma Peter CHIEF COMMERCIAL OFFICER | Gift 10b5-1 | −1,078 | 117,993 | ||
| 2025-10-31 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −5,591 | $35.00 | $196K | 119,071 |
| 2025-10-31 | Coughlin Timothy Director | Option exercise 10b5-1 | +8,000 | $16.33 | $131K | 63,500 |
| 2025-10-31 | Coughlin Timothy Director | Option exercise 10b5-1 | +10,000 | $17.44 | $174K | 73,500 |
| 2025-10-31 | Coughlin Timothy Director | Sale 10b5-1 | −18,000 | $35.03 | $631K | 55,500 |
| 2025-10-31 | Coughlin Timothy Director | Option exercise · Director stock option (right to buy) 10b5-1 | −8,000 | 0 | ||
| 2025-10-31 | Coughlin Timothy Director | Option exercise · Director stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-10-29 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +27,128 | $15.46 | $419K | 446,301 |
| 2025-10-29 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −27,128 | $30.12 | $817K | 419,173 |
| 2025-10-29 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −27,128 | 180,000 | ||
| 2025-10-28 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −2,662 | $30.00 | $80K | 124,662 |
| 2025-10-28 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +92,872 | $15.46 | $1.4M | 512,045 |
| 2025-10-28 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −92,872 | $30.38 | $2.8M | 419,173 |
| 2025-10-28 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −92,872 | 207,128 | ||
| 2025-09-23 | Heerma Peter CHIEF COMMERCIAL OFFICER | Gift 10b5-1 | −891 | 127,324 | ||
| 2025-09-22 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +10,000 | $19.08 | $191K | 99,878 |
| 2025-09-22 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −10,000 | $25.00 | $250K | 89,878 |
| 2025-09-22 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 40,000 |
Page 16 of 51 · 1,020 trades